1. Home
  2. INCY vs VRSK Comparison

INCY vs VRSK Comparison

Compare INCY & VRSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Incyte Corp.

INCY

Incyte Corp.

N/A

Current Price

$114.90

Market Cap

24.5B

Sector

Health Care

ML Signal

N/A

Logo Verisk Analytics Inc.

VRSK

Verisk Analytics Inc.

N/A

Current Price

$203.10

Market Cap

26.4B

ML Signal

N/A

Company Overview

Basic Information
Metric
INCY
VRSK
Founded
1991
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
24.5B
26.4B
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
INCY
VRSK
Price
$114.90
$203.10
Analyst Decision
Buy
Buy
Analyst Count
28
20
Target Price
$132.17
★ $234.25
AVG Volume (30 Days)
★ 1.5M
1.1M
Earning Date
10-29-2026
11-05-2026
Dividend Yield
N/A
★ 1.00%
EPS Growth
★ 4173.33
N/A
EPS
0.50
★ 5.18
Revenue
★ $3,394,635,000.00
N/A
Revenue This Year
$17.74
$4.72
Revenue Next Year
$4.38
$6.77
P/E Ratio
$231.80
★ $38.71
Revenue Growth
★ 13.67
N/A
52 Week Low
$89.25
$155.94
52 Week High
$132.60
$227.16

Technical Indicators

Market Signals
Indicator
INCY
VRSK
Relative Strength Index (RSI) 41.81 55.06
Support Level $109.78 $197.59
Resistance Level $119.29 $204.95
Average True Range (ATR) 3.73 6.77
MACD -0.53 -0.97
Stochastic Oscillator 3.94 41.22

Price Performance

Historical Comparison
INCY
VRSK

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

About VRSK Verisk Analytics Inc.

Verisk is a leading data, analytics, and technology provider for property-casualty insurers. Verisk traces its history to Insurance Services Office, a nonprofit advisory organization founded in 1971 by US P&C insurers. ISO was formed as an association of insurance companies to assist with a variety of insurance use cases, such as reporting to regulators, defining policies, and determining independent premium rates. As the firm expanded its use cases, it became a for-profit company, renamed Verisk, and went public in 2009.Verisk's single segment (insurance) provides underwriting solutions, including forms, rules, loss costs, and catastrophe modeling. For claims, Verisk's solutions include property repair estimates and antifraud tools. About 83% of Verisk's revenue is US-based.

Share on Social Networks: